Cordis stent gets FDA panel recommendation

Interventional technology developer Cordis has received an approval recommendation from the Circulatory System Devices Panel of the Food and Drug Administration for its Cordis Carotid System.

The system is intended for use as a minimally invasive treatment alternative to carotid endarterectomy in high-risk patients, according to the Warren, NJ-based subsidiary of Johnson & Johnson.

The product includes two components: the Precise Nitinol Self-Expanding Stent and the Angioguard Emboli Capture Guidewire. These products are currently approved for use in carotid arteries outside the U.S., the company said.

By staff writers
April 22, 2004

Related Reading

Cordis stent gets CE OK, April 8, 2004

Guidant, Johnson & Johnson ink stent deal, February 27, 2004

Cordis stent gets FDA OK, September 5, 2003

Cordis files suit against Boston Scientific, January 15, 2003

Cordis debuts new biliary stent, August 27, 2002

Copyright © 2004

Page 1 of 180
Next Page